Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: AJAG who wrote (2598)	5/3/1999 10:19:00 PM
From: synchro	Read Replies (2) \| Respond to of 10280

<< Does anybody think that Sepracor is only worth one sixteenth of Amgen's market value? >> Count me as one. Actually, it should be worth less at this stage of its development, hype notwithstanding. Amgen is enormously profitable, and its R&D is financed with operating earnings. Separacor is built on hope, FDA's good will (that may or may not be forthcoming), and current Wall Street enthusiasm (which seems to be rapidly deflating). Its R&D is funded, as of now and the foreseeable future, by investor charity. Sepracor is worth buying at some price, but is it in the league of the Big Six (AMGN, BGEN, CHIR, GENZ, GNE, IMNX)? Not yet.